Related Experiment Video

Updated: Aug 14, 2026

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
07:35

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

Molecular stool testing for the early detection of colorectal cancer: swan song for p53?

G Ferretti, A Felici, M Ciccarese

    Annals of Oncology : Official Journal of the European Society for Medical Oncology
    |November 18, 2005
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
    28:15

    Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

    Published on: July 28, 2010

    Quantification of Colonic Stem Cell Mutations
    07:53

    Quantification of Colonic Stem Cell Mutations

    Published on: September 25, 2015

    Related Experiment Videos

    Last Updated: Aug 14, 2026

    Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
    07:35

    Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

    Published on: June 8, 2020

    Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
    28:15

    Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

    Published on: July 28, 2010

    Quantification of Colonic Stem Cell Mutations
    07:53

    Quantification of Colonic Stem Cell Mutations

    Published on: September 25, 2015

    Related Concept Videos

    Serum Laboratory Studies, Stool Test, Breath Test01:30

    Serum Laboratory Studies, Stool Test, Breath Test

    Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...

    Articles linked to this work by shared authors, journal, and citation graph.

    Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis.

    ESMO open·2026

    A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    The role of germline mutations in non-small cell lung cancer: A systematic review of emerging genetic drivers and clinical implications.

    Critical reviews in oncology/hematology·2026

    Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trials.

    ESMO open·2026

    Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers.

    ESMO open·2025

    PREDICTIVE BRCA GENETIC TESTING IN ITALIAN PATIENTS WITH BREAST CANCER: A POSITION PAPER OF ITALIAN SCIENTIFIC SOCIETIES [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)].

    Cancer treatment reviews·2025

    Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Adjuvant chemotherapy with cisplatin and gemcitabine compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial).

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us